Advertisement

Endocrine

pp 1–9 | Cite as

Surgical management considerations in cystic prolactinomas—a single center case series

  • Edin NevzatiEmail author
  • Grégoire P. Chatain
  • Steven B. Carr
  • Kevin O. Lillehei
  • Janice M. Kerr
Endocrine Surgery
  • 10 Downloads

Abstract

Purpose

The optimal treatment of prolactinomas with a predominantly cystic component remains poorly defined. The cystic tumor component is considered to respond less favorably to medical treatment, thereby advocating surgical management. The purpose of this study was to assess remission rates in surgically treated cystic prolactinomas, and to compare outcomes to similarly treated solid micro- and macroprolactinomas.

Methods

Clinical and imaging data were retrospectively compiled from 56 patients who underwent transsphenoidal resection, for symptomatic prolactinomas, from 2004 to 2018, at a single academic institution. Pituitary adenomas were subdivided according to tumor size and tumor consistency: cystic prolactinomas (>50% cystic tumor component) n = 17; solid microprolactinomas (<10 mm) n = 10; and solid macroprolactinomas (≥10 mm) n = 29. Remission was defined as a prolactin level of <10 ng/dl either immediately postoperative or at a later time point.

Results

Median tumor size was 15 mm for cystic prolactinomas, 7 mm for solid microprolactinomas, and 25.5 mm for solid macroprolactinomas. Remission was achieved in 76% (n = 13/17) of surgically treated cystic prolactinomas, 100% (n = 10/10) of solid microprolactinomas, and 24% (n = 7/29) of solid macroprolactinomas. More than 44% of solid macroprolactinomas had a Knosp grade > 3, while most cystic prolactinomas (93.8%) and all solid microprolactinomas (100%) had a Knosp grade ≤ 2.

Conclusions

Despite their large tumor size (≥10 mm), high remission rates can be expected with surgically treated cystic prolactinomas. This case series of cystic prolactinomas demonstrates the successful use of transsphenoidal surgery as a favorable, and a potentially curative alternative to dopaminergic therapy in this patient population.

Keywords

Cystic prolactinoma Microprolactinoma Macroprolactinoma Transsphenoidal surgery Surgical remission 

Notes

Acknowledgements

We thank Patrick William Hosokawa for the support in statistical analysis, Surgical Outcome and Applied Research, Department of Surgery, University of Colorado School of Medicine.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65(2), 265–273 (2006).  https://doi.org/10.1111/j.1365-2265.2006.02562.x CrossRefGoogle Scholar
  2. 2.
    J.N. Carter, J.E. Tyson, G. Tolis, S. Van Vliet, C. Faiman, H.G. Friesen, Prolactin-screening tumors and hypogonadism in 22 men. N. Engl. J. Med 299(16), 847–852 (1978).  https://doi.org/10.1056/NEJM197810192991602 CrossRefPubMedGoogle Scholar
  3. 3.
    M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27(5), 485–534 (2006).  https://doi.org/10.1210/er.2005-9998 CrossRefPubMedGoogle Scholar
  4. 4.
    S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, S. Endocrine, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011).  https://doi.org/10.1210/jc.2010-1692 CrossRefPubMedGoogle Scholar
  5. 5.
    W.J. Inder, M.R. Macfarlane, Hyperprolactinaemia associated with a complex cystic pituitary mass: medical versus surgical therapy. Intern. Med. J. 34(9–10), 573–576 (2004).  https://doi.org/10.1111/j.1445-5994.2004.00675.x CrossRefPubMedGoogle Scholar
  6. 6.
    World Medical Association, Declaration of Helsinki. Ethical principles for medical research involving human subjects. J. Indian Med. Assoc. 107(6), 403–405 (2009)Google Scholar
  7. 7.
    R.A. Agha, A.J. Fowler, S. Rajmohan, I. Barai, D.P. Orgill, P. Group, Preferred reporting of case series in surgery; the PROCESS guidelines. Int J. Surg. 36(Pt A), 319–323 (2016).  https://doi.org/10.1016/j.ijsu.2016.10.025 CrossRefPubMedGoogle Scholar
  8. 8.
    G. Mohr, J. Hardy, Hemorrhage, necrosis, and apoplexy in pituitary adenomas. Surg. Neurol. 18(3), 181–189 (1982)CrossRefGoogle Scholar
  9. 9.
    E. Knosp, E. Steiner, K. Kitz, C. Matula, Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4), 610–617 (1993). discussion 617–618PubMedGoogle Scholar
  10. 10.
    A.S. Micko, A. Wohrer, S. Wolfsberger, E. Knosp, Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J. Neurosurg. 122(4), 803–811 (2015).  https://doi.org/10.3171/2014.12.JNS141083 CrossRefPubMedGoogle Scholar
  11. 11.
    S. Nakasu, Y. Nakasu, K. Kyoshima, K. Watanabe, J. Handa, H. Okabe, Pituitary adenoma with multiple ciliated cysts: transitional cell tumor? Surg. Neurol. 31(1), 41–48 (1989)CrossRefGoogle Scholar
  12. 12.
    G.S. Pearl, Y. Takei, M. Kurisaka, S. Seyama, G.T. Tindall, Cystic prolactinoma: a variant of “transitional cell tumor” of the pituitary. Am. J. Surg. Pathol. 5(1), 85–90 (1981)CrossRefGoogle Scholar
  13. 13.
    B. Bahuleyan, G. Menon, S. Nair, B.R. Rao, H.V. Easwer, K. Krishna, Non-surgical management of cystic prolactinomas. J. Clin. Neurosci. 16(11), 1421–1424 (2009).  https://doi.org/10.1016/j.jocn.2009.03.024 CrossRefPubMedGoogle Scholar
  14. 14.
    A. Faje, P. Chunharojrith, J. Nency, B.M. Biller, B. Swearingen, A. Klibanski, Dopamine agonists can reduce cystic prolactinomas. J. Clin. Endocrinol. Metab. 101(10), 3709–3715 (2016).  https://doi.org/10.1210/jc.2016-2008 CrossRefPubMedGoogle Scholar
  15. 15.
    A. Colao, Pituitary tumours: the prolactinoma. Best. Pr. Res Clin. Endocrinol. Metab. 23(5), 575–596 (2009).  https://doi.org/10.1016/j.beem.2009.05.003 CrossRefGoogle Scholar
  16. 16.
    A.P. Amar, W.T. Couldwell, J.C. Chen, M.H. Weiss, Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J. Neurosurg. 97(2), 307–314 (2002).  https://doi.org/10.3171/jns.2002.97.2.0307 CrossRefPubMedGoogle Scholar
  17. 17.
    R. Fahlbusch, M. Buchfelder, Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochir. 92(1–4), 93–99 (1988)CrossRefGoogle Scholar
  18. 18.
    X.F. Shou, S.Q. Li, Y.F. Wang, Y. Zhao, P.F. Jia, L.F. Zhou, Treatment of pituitary adenomas with a transsphenoidal approach. Neurosurgery 56(2), 249–256 (2005). discussion 249–256CrossRefGoogle Scholar
  19. 19.
    J.P. Sheehan, D. Kondziolka, J. Flickinger, L.D. Lunsford, Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J. Neurosurg. 97(5 Suppl), 408–414 (2002).  https://doi.org/10.3171/jns.2002.97. supplementCrossRefPubMedGoogle Scholar
  20. 20.
    E. Delgrange, T. Gustin, Cystic macroprolactinoma: primary medical treatment? Intern. Med. J. 35(11), 687 (2005).  https://doi.org/10.1111/j.1445-5994.2005.00941.x. author reply 688CrossRefPubMedGoogle Scholar
  21. 21.
    J. Kreutzer, R. Buslei, H. Wallaschofski, B. Hofmann, C. Nimsky, R. Fahlbusch, M. Buchfelder, Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158(1), 11–18 (2008).  https://doi.org/10.1530/EJE-07-0248 CrossRefPubMedGoogle Scholar
  22. 22.
    T. Ogiwara, T. Horiuchi, A. Nagm, T. Goto, K. Hongo, Significance of surgical management for cystic prolactinoma. Pituitary 20(2), 225–230 (2017).  https://doi.org/10.1007/s11102-016-0766-6 CrossRefPubMedGoogle Scholar
  23. 23.
    C. Zhang, X. Ding, Y. Lu, L. Hu, G. Hu, Cerebrospinal fluid rhinorrhoea following transsphenoidal surgery for pituitary adenoma: experience in a Chinese centre. Acta Otorhinolaryngol. Ital. 37(4), 303–307 (2017).  https://doi.org/10.14639/0392-100X-1086 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    M. Menucci, A. Quinones-Hinojosa, P. Burger, R. Salvatori, Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14(1), 68–74 (2011).  https://doi.org/10.1007/s11102-010-0261-4 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    A.S. Dumont, E.C. Nemergut 2nd, J.A. Jane Jr., E.R. Laws Jr., Postoperative care following pituitary surgery. J. Intensive Care Med. 20(3), 127–140 (2005).  https://doi.org/10.1177/0885066605275247 CrossRefPubMedGoogle Scholar
  26. 26.
    P.R. Jethwa, T.D. Patel, A.F. Hajart, J.A. Eloy, W.T. Couldwell, J.K. Liu, Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. World Neurosurg. 87, 65–76 (2016).  https://doi.org/10.1016/j.wneu.2015.10.090 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurosurgeryUniversity of Colorado School of MedicineAuroraUSA
  2. 2.Division of NeurosurgeryUniversity of Missouri School of MedicineColumbiaUSA
  3. 3.Department of Medicine, Division of Endocrinology, Metabolism and DiabetesUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations